Solventum Corporation

SOLV ·Healthcare, Medical Devices, United States
Financial Statements › Cash Flow Statement
Annual Quarterly

Cash Flow Statement

Line Item FY2025 FY2024 FY2023 FY2022
Operating Activities
Net Income $1.56B $479.0M $1.35B $1.34B
Depreciation & Amortization $489.0M $555.0M $561.0M $578.0M
Depreciation $151.0M $181.0M $164.0M $177.0M
Amortization $312.0M $349.0M $365.0M $373.0M
Stock-Based Compensation $161.0M $112.0M $39.0M $37.0M
Net Cash from Operating Activities $369.0M $1.19B $1.92B $1.68B
Investing Activities
Capital Expenditures $379.0M $380.0M $290.0M $251.0M
Business Acquisitions $696.0M $0 $0 —
Net Cash from Investing Activities $2.80B $-380.0M $-230.0M $-253.0M
Financing Activities
Dividends Paid — — — —
Stock Repurchases — — — —
Net Cash from Financing Activities $-3.06B $-240.0M $-1.55B $-1.46B
Net Change in Cash $116.0M $568.0M $133.0M $-30.0M
Free Cash Flow $-10.0M $805.0M $1.63B $1.43B